Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 14 , ISSUE 1 ( January-February, 2022 ) > List of Articles


Growing Teratoma Syndrome: A Review Article

Richi Khandelwal, Sushil K Giri

Keywords : Chemotherapy, Complex cyst, Growing teratoma syndrome

Citation Information : Khandelwal R, Giri SK. Growing Teratoma Syndrome: A Review Article. J South Asian Feder Obs Gynae 2022; 14 (1):81-83.

DOI: 10.5005/jp-journals-10006-1989

License: CC BY-NC 4.0

Published Online: 13-04-2022

Copyright Statement:  Copyright © 2022; The Author(s).


It is a rare entity described among patients with non-seminomatous germ cell tumors (NSGCTs), characterized by enlarging metastatic masses despite appropriate systemic chemotherapy and normalized serum markers. The prevalence of growing teratoma syndrome (GTS) is only 1.9–7.6% after testicular NSGCT and 12% after ovarian germ cell tumor although more commonly seen is post-testicular and generally affects young adults and adolescents. The etiology remains unclear. They are mostly asymptomatic but abdominal pain/distension may be seen. Their prognosis is highly dependent on the timing of diagnosis, and early diagnosis has an excellent prognosis. There is no effective medical treatment for GTS and it is unresponsive to chemotherapy or radiotherapy. Total surgical removal of mature teratomas is currently the gold standard treatment of this condition. Hence, in this article, we have covered the complete review of this rare entity called GTS.

PDF Share
  1. Logothetis CJ, Samuels ML, Trindade A, et al. The growing teratoma syndrome. Cancer 1982;50:1629–1635. PubMed: 6288220.
  2. Jeffery GM, Theaker JM, Lee AH, et al. The growing teratoma syndrome. Br J Urol 1991;67:195–202. PubMed: 2004236.
  3. Carr BI, Gilchrist KW, Carbone PP. The variable transformation in metastases from testicular germ cell tumors: the need for selective biopsy. J Urol 1981;126:52–54. PubMed: 7253077.
  4. DiSaia PJ, Saltz A, Kagan AR, et al. Chemotherapeutic re of immature teratoma of the ovary. Obstet Gynecol 1977;49:346–350. PubMed: 65751.
  5. Hong WK, Wittes RE, Hajdu ST, et al. The evolution of mature teratoma from malignant testicular tumors. Cancer 1977;40:2987–2992. PubMed: 563283.
  6. Andre F, Fizazi K, Culine S, et al. The growing teratoma syndrome: Results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000;36:1389–1394. PubMed: 10899652.
  7. O'Callaghan AM, Katapodis O, Ellison DW, et al. The growing teratoma syndrome in a nongerminomatous germ cell tumor of the pineal gland. Cancer 1997;80:942–947. PubMed: 9307195.
  8. Spiess PE, Tannir NM, Tu SM, et al. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 2007;110: 2700–2708. PubMed: 17948916.
  9. Aide N, Comoz F, Savin E. Enlarging residual mass after treatment of a nonseminomatous germ cell tumor: growing teratoma syndrome or cancer recurrence? J Clin Oncol 2007;25:4494–4496. PubMed: 17906212.
  10. Inaoka T, Takahashi K, Yamada T, et al. The growing teratoma syndrome secondary to immature teratoma of the ovary. Eur Radiol 2003;13:2115–2118. PubMed: 12928961.
  11. Tangjitgamol S, Manusirivithaya S, Leelahakorn S, et al. The growing teratoma syndrome: a case report and a review of literature. Int J Gynecol Cancer 2006;16:384–390. PubMed: 16515629.
  12. Maroto P, Tabernero JM, Villavicencio H, et al. Growing teratoma syndrome: experience of a single institution. Eur Urol 1997;32: 305–309. PubMed: 9358218.
  13. Byrd K, Stany MP, Herbold NC, et al. Growing teratoma syndrome: brief communication and algorithm for management. Aust N Z J Obstet Gynaecol 2013;53(3):318–321. DOI: 10.1111/ajo.12084.
  14. Tonkin KS, Rustin GJS, Wignall B, et al. Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased. Eur J Cancer Clin Oncol 1989;25:1739–1743. PubMed: 2483686.
  15. Rustin GJS, Kaye SB, Williams CJ, et al. Response of differentiated but not anaplastic teratoma to interferon. Br J Cancer 1982;50:611–616. PMCID: PMC1976992.
  16. Mego M, Reckova M, Sycova-Mila Z, et al. Bevacizumab in a growing teratoma syndrome. Case report. Ann Oncol 2007;18(5):962–963. PubMed: 17434900.
  17. Narayan V, Hwang WT, Lal P, et al. Cyclin-dependent kinase 4/6 inhibition for the treatment of unresectable mature teratoma: long-term follow-up of a phase II study. Clin Genitourin Cancer 2016;14(6):504–510. DOI: 10.1016/j.clgc.2016.03.010.
  18. Spiess PE, Kassouf W, Brown GA, et al. Surgical management of growing teratoma syndrome: the MD Anderson cancer center. Experience J Urol 2007;177:1330–1334. PubMed: 17382725.
  19. Ravi R. Growing teratoma syndrome. Urol Int 1995;55:226–228. PubMed: 8588272.
  20. Beck SD, Foster RS, Bihrle R, et al. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. J Urol 2009;181(6):2526–2532. DOI: 10.1016/j.juro.2009.01.116.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.